Daryl Tan-Yeung Lau, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B, Chronic | 32 | 2024 | 392 | 6.980 |
Why?
|
| Hepatitis B virus | 33 | 2024 | 509 | 5.060 |
Why?
|
| Hepatitis B Surface Antigens | 13 | 2024 | 298 | 3.340 |
Why?
|
| Hepatitis B | 14 | 2023 | 692 | 3.190 |
Why?
|
| Hepatitis B e Antigens | 15 | 2023 | 132 | 2.270 |
Why?
|
| Hepatitis B Antibodies | 4 | 2024 | 155 | 1.740 |
Why?
|
| Hepatitis B Core Antigens | 6 | 2023 | 89 | 1.560 |
Why?
|
| Antiviral Agents | 29 | 2023 | 2977 | 1.340 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2022 | 2215 | 1.290 |
Why?
|
| DNA, Viral | 19 | 2023 | 2164 | 1.220 |
Why?
|
| Hepatitis C, Chronic | 9 | 2022 | 1019 | 1.160 |
Why?
|
| Liver Neoplasms | 10 | 2022 | 4212 | 1.020 |
Why?
|
| Cryoglobulinemia | 1 | 2022 | 86 | 0.800 |
Why?
|
| Hepatitis C | 7 | 2022 | 1579 | 0.760 |
Why?
|
| Hepacivirus | 11 | 2022 | 1370 | 0.690 |
Why?
|
| Virus Activation | 2 | 2018 | 314 | 0.670 |
Why?
|
| Interferon-alpha | 6 | 2014 | 895 | 0.660 |
Why?
|
| Liver Cirrhosis | 9 | 2022 | 1842 | 0.630 |
Why?
|
| Superinfection | 1 | 2018 | 64 | 0.620 |
Why?
|
| Hepatitis E | 1 | 2018 | 74 | 0.580 |
Why?
|
| Alanine Transaminase | 10 | 2021 | 577 | 0.570 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2022 | 681 | 0.560 |
Why?
|
| Liver | 10 | 2020 | 7298 | 0.530 |
Why?
|
| Kupffer Cells | 2 | 2013 | 143 | 0.520 |
Why?
|
| RNA, Viral | 4 | 2021 | 2803 | 0.380 |
Why?
|
| Interferons | 5 | 2019 | 698 | 0.370 |
Why?
|
| Interferon Regulatory Factor-3 | 2 | 2008 | 132 | 0.350 |
Why?
|
| Aspartate Aminotransferases | 4 | 2015 | 400 | 0.280 |
Why?
|
| Hepatitis A Antibodies | 1 | 2005 | 18 | 0.270 |
Why?
|
| Viral Load | 7 | 2019 | 3261 | 0.250 |
Why?
|
| Antigens, Surface | 2 | 2023 | 1609 | 0.240 |
Why?
|
| Immune Tolerance | 1 | 2012 | 2183 | 0.230 |
Why?
|
| Platelet Count | 3 | 2015 | 758 | 0.220 |
Why?
|
| Genotype | 8 | 2021 | 12677 | 0.220 |
Why?
|
| North America | 3 | 2021 | 1240 | 0.220 |
Why?
|
| Immunity, Innate | 2 | 2012 | 2954 | 0.220 |
Why?
|
| Cryoglobulins | 1 | 2022 | 58 | 0.210 |
Why?
|
| Mutation | 2 | 2024 | 29406 | 0.210 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2009 | 242 | 0.200 |
Why?
|
| Polyethylene Glycols | 3 | 2022 | 1163 | 0.200 |
Why?
|
| Adult | 33 | 2024 | 212371 | 0.200 |
Why?
|
| Humans | 64 | 2024 | 735458 | 0.190 |
Why?
|
| alpha-Fetoproteins | 1 | 2022 | 222 | 0.190 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2020 | 29 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2024 | 346 | 0.190 |
Why?
|
| Biopsy | 7 | 2020 | 6666 | 0.180 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1764 | 0.180 |
Why?
|
| Liver Function Tests | 3 | 2019 | 507 | 0.170 |
Why?
|
| Adenine | 1 | 2004 | 962 | 0.160 |
Why?
|
| Virus Replication | 6 | 2022 | 2456 | 0.160 |
Why?
|
| Liver Diseases | 2 | 2013 | 1241 | 0.160 |
Why?
|
| Female | 36 | 2024 | 376708 | 0.160 |
Why?
|
| Hepatitis B Vaccines | 1 | 2019 | 183 | 0.150 |
Why?
|
| Actins | 1 | 2005 | 2076 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2019 | 338 | 0.150 |
Why?
|
| Liver Failure, Acute | 1 | 2018 | 166 | 0.140 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 5383 | 0.140 |
Why?
|
| Viremia | 1 | 2019 | 719 | 0.140 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 11781 | 0.140 |
Why?
|
| Genetic Variation | 4 | 2021 | 6412 | 0.130 |
Why?
|
| Middle Aged | 23 | 2024 | 211305 | 0.130 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 3030 | 0.130 |
Why?
|
| RNA | 3 | 2023 | 2690 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2018 | 2031 | 0.130 |
Why?
|
| Lamivudine | 3 | 2007 | 348 | 0.130 |
Why?
|
| Guanine | 1 | 2016 | 272 | 0.130 |
Why?
|
| Fatigue | 1 | 2022 | 1503 | 0.120 |
Why?
|
| Male | 30 | 2024 | 346169 | 0.120 |
Why?
|
| Electricity | 1 | 2015 | 185 | 0.120 |
Why?
|
| Microtechnology | 1 | 2014 | 69 | 0.120 |
Why?
|
| Hepatitis B Antigens | 1 | 2013 | 39 | 0.120 |
Why?
|
| Young Adult | 8 | 2024 | 56151 | 0.120 |
Why?
|
| Gastroenterology | 1 | 2020 | 532 | 0.110 |
Why?
|
| Hepatocytes | 2 | 2012 | 1189 | 0.110 |
Why?
|
| Puerperal Disorders | 1 | 2016 | 293 | 0.110 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2015 | 212 | 0.110 |
Why?
|
| STAT Transcription Factors | 1 | 2014 | 180 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 9952 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 9234 | 0.110 |
Why?
|
| Janus Kinases | 1 | 2014 | 239 | 0.110 |
Why?
|
| Host-Pathogen Interactions | 2 | 2018 | 1446 | 0.110 |
Why?
|
| DNA, Circular | 1 | 2022 | 96 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2019 | 1308 | 0.100 |
Why?
|
| Lectins | 1 | 2013 | 496 | 0.100 |
Why?
|
| Recombinant Proteins | 4 | 2014 | 6511 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 255 | 0.100 |
Why?
|
| Prevalence | 3 | 2024 | 14976 | 0.090 |
Why?
|
| Nanostructures | 1 | 2015 | 534 | 0.090 |
Why?
|
| Aged | 10 | 2024 | 161495 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2015 | 495 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 4692 | 0.090 |
Why?
|
| Age Factors | 3 | 2022 | 17982 | 0.090 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 844 | 0.090 |
Why?
|
| Hepatitis C Antigens | 1 | 2009 | 34 | 0.090 |
Why?
|
| Algorithms | 4 | 2021 | 13734 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 13817 | 0.080 |
Why?
|
| Receptors, Virus | 1 | 2012 | 628 | 0.080 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 647 | 0.080 |
Why?
|
| United States | 9 | 2024 | 69005 | 0.080 |
Why?
|
| Viral Core Proteins | 1 | 2009 | 162 | 0.080 |
Why?
|
| Nanotechnology | 1 | 2014 | 693 | 0.080 |
Why?
|
| Interferon Type I | 1 | 2012 | 536 | 0.080 |
Why?
|
| Serologic Tests | 2 | 2022 | 369 | 0.080 |
Why?
|
| Inflammasomes | 1 | 2013 | 508 | 0.080 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 510 | 0.080 |
Why?
|
| Quantum Dots | 1 | 2009 | 168 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 11203 | 0.080 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2009 | 265 | 0.070 |
Why?
|
| Mass Screening | 1 | 2003 | 5167 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 958 | 0.070 |
Why?
|
| Hepatitis, Chronic | 1 | 2006 | 52 | 0.070 |
Why?
|
| Hepatitis A virus | 1 | 2005 | 15 | 0.070 |
Why?
|
| Drug Resistance, Viral | 2 | 2011 | 827 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2021 | 52611 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 38356 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2004 | 613 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 56770 | 0.060 |
Why?
|
| Incidence | 4 | 2022 | 20493 | 0.060 |
Why?
|
| Chromatography | 1 | 2003 | 193 | 0.060 |
Why?
|
| Models, Theoretical | 2 | 2012 | 3516 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2015 | 18842 | 0.060 |
Why?
|
| Cohort Studies | 5 | 2023 | 39931 | 0.050 |
Why?
|
| Pregnancy | 3 | 2019 | 28985 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 615 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2008 | 725 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 4444 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 1880 | 0.050 |
Why?
|
| Canada | 2 | 2019 | 2034 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 40812 | 0.050 |
Why?
|
| Adolescent | 5 | 2021 | 85125 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 3762 | 0.050 |
Why?
|
| ROC Curve | 3 | 2020 | 3457 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2013 | 2226 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 384 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2013 | 4906 | 0.040 |
Why?
|
| Phenotype | 4 | 2019 | 16066 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2018 | 76887 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 14501 | 0.040 |
Why?
|
| Child | 3 | 2022 | 77344 | 0.040 |
Why?
|
| Population Groups | 1 | 2019 | 201 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 6364 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2019 | 386 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 3712 | 0.040 |
Why?
|
| Neutropenia | 1 | 2003 | 877 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2018 | 9009 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5612 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2008 | 2676 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3788 | 0.040 |
Why?
|
| Carrier State | 1 | 2019 | 517 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2020 | 1688 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 2862 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2020 | 21459 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2003 | 1325 | 0.030 |
Why?
|
| Transaminases | 1 | 2015 | 192 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 258 | 0.030 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2014 | 9 | 0.030 |
Why?
|
| Orthomyxoviridae | 1 | 2015 | 146 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 658 | 0.030 |
Why?
|
| Time Factors | 3 | 2018 | 39212 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 14815 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 15306 | 0.030 |
Why?
|
| Alaska | 1 | 2013 | 69 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 24714 | 0.030 |
Why?
|
| Disease Progression | 2 | 2022 | 13117 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2022 | 62430 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2014 | 172 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 325 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1881 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2013 | 702 | 0.030 |
Why?
|
| Publishing | 1 | 2020 | 817 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2015 | 494 | 0.030 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 16463 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2013 | 222 | 0.030 |
Why?
|
| Cell Line | 2 | 2019 | 15617 | 0.030 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2013 | 171 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 3500 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2015 | 587 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2018 | 1121 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 4593 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2014 | 446 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2007 | 8256 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2507 | 0.020 |
Why?
|
| DNA Primers | 2 | 2005 | 2820 | 0.020 |
Why?
|
| Proteins | 1 | 2005 | 5975 | 0.020 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2014 | 419 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2015 | 1164 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2014 | 778 | 0.020 |
Why?
|
| Microfluidics | 1 | 2015 | 661 | 0.020 |
Why?
|
| Environment | 1 | 2015 | 1105 | 0.020 |
Why?
|
| Chemokines | 1 | 2013 | 949 | 0.020 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2013 | 574 | 0.020 |
Why?
|
| Temperature | 1 | 2015 | 2184 | 0.020 |
Why?
|
| Linear Models | 1 | 2018 | 5783 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 2178 | 0.020 |
Why?
|
| Survivors | 1 | 1998 | 2269 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 1544 | 0.020 |
Why?
|
| RNA, Double-Stranded | 1 | 2009 | 290 | 0.020 |
Why?
|
| Prognosis | 2 | 2022 | 28548 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2013 | 1510 | 0.020 |
Why?
|
| Equipment Design | 1 | 2015 | 3499 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 3110 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3606 | 0.020 |
Why?
|
| Replicon | 1 | 2006 | 34 | 0.020 |
Why?
|
| Recurrence | 1 | 2018 | 8232 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2014 | 1692 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 6354 | 0.020 |
Why?
|
| Vaccination | 1 | 2018 | 3200 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2007 | 577 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2013 | 12721 | 0.020 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2005 | 169 | 0.010 |
Why?
|
| Base Sequence | 2 | 2005 | 12513 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 19673 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 12840 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 11939 | 0.010 |
Why?
|
| Computer Systems | 1 | 2004 | 470 | 0.010 |
Why?
|
| Developing Countries | 1 | 2014 | 2754 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 2960 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2006 | 1600 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 3720 | 0.010 |
Why?
|
| Public Health | 1 | 2014 | 2572 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13074 | 0.010 |
Why?
|
| Infant | 2 | 2019 | 34948 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2015 | 6097 | 0.010 |
Why?
|
| Gene Expression | 1 | 2014 | 7578 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2014 | 22952 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2015 | 10250 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 15221 | 0.010 |
Why?
|
| Cytokines | 1 | 2013 | 7175 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 19878 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 5780 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 3340 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 6068 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 35374 | 0.010 |
Why?
|
| Mitochondria | 1 | 2006 | 3471 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 7764 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 7159 | 0.010 |
Why?
|